Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

UNITED STATES: FDA Approves Hepatitis B Viral DNA Test
The first hepatitis B virus (HBV) nucleic acid test to measure the amount of viral DNA in a patient's blood has won Food and Drug Administration approval. 'The COBAS TaqMan HBV Test extracts and then amplifies sections of viral DNA from human plasma or

Toll rises to 121 in Uganda hepatitis epidemic
A hepatitis E epidemic has killed 121 people in northern Uganda, where it erupted in October last year, a health ministry official said Thursday. A diagram showing the hepatitis C virus © AFP/File KAMPALA (AFP) - The outbreak has mainly affected

Roche Molecular Diagnostics Wins FDA OK for Hepatitis B Test
A hepatitis B viral load test, developed by Roche Molecular Diagnostics in Pleasanton, was approved by the Food and Drug Administration.

UPDATES AND COMMENTARY RSS Feed

HCV Genotype 1 Viral Loads Decline
A six-month follow-up to Intercell's Phase II trial of their Hepatitis C vaccine with a topical toll-like receptor agonist showed a significant reduction in viral load. While data from two weeks after the vaccination series showed promise, participants with Hepatitis...

Former Anti-Itch Drug Useful Against Hep C
California scientists have found that an old antihistamine drastically reduces Hepatitis C viral replication....

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

Fibrosis & Cirrhosis

Cirrhosis

Pathology

A key ingredient is fibrosis, whose development and extent depends upon the interplay of many factors. The progression of fibrosis to cirrhosis similarly depends upon the extent of injury, the presence of continuing damage, and the liver's reaction to these agents. Thus the lesion of cirrhosis is not static, and the features seen depend upon the activity and stage of the disease involved. Classification of pathology in cirrhosis may indicate the prominent features found in any one specimen but does not provide etiologic information nor a complete morphologic description of the pathology.

The common classification of the histopathology in cirrhosis: Micronodular cirrhosis is characterized by thin, regular bands of connective tissue and by small nodules (up to 1 cm in diameter) that vary little in size. Typically, terminal hepatic venules or portal tracts are difficult to identify. Macronodular cirrhosis is characterized by nodules that vary in size (up to 5 cm in diameter), are often multinodular, and contain portal tracts and terminal hepatic venules. Broad fibrous bands of varying thickness surround the nodules. Collapse of the normal liver architecture is suggested by the concentration of portal tracts within the fibrous scars. Mixed cirrhosis (incomplete septal cirrhosis) combines elements of micro- and macronodular cirrhosis. Regeneration within the nodules is less conspicuous, and hepatic venules and portal tracts are seen more often.

Source:The Merck Manual

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 07 Sep 2008